FluMist(R) Now Available for the 2008-2009 Flu Season
GAITHERSBURG, Md., Aug. 4 /PRNewswire/ — MedImmune announced today that it began shipping FluMist(R) (Influenza Virus Vaccine Live, Intranasal) on July 31 for the 2008-2009 influenza season. Early and wide availability of FluMist is a key component in maximizing opportunities to vaccinate an additional 30 million children and teenagers through the age of 18 years who are now recommended by the U.S. Centers for Disease Control and Prevention’s (CDC) Advisory Committee on Immunization Practices (ACIP) to be vaccinated annually against influenza.
(Photo: http://www.newscom.com/cgi-bin/prnh/20080804/NEM027 )
The CDC also advises that flu vaccine be administered every year as soon as it becomes available. Results of a recent analysis reported by MedImmune at the annual meeting of the Pediatric Academic Societies (PAS) revealed that starting vaccination against influenza in August may help reach an additional 10.7 million children while they are at healthcare provider offices for already-scheduled visits.
“To meet the goal of vaccinating every school-age child and teenager against the flu, vaccination practices must shift to include opportunities across a longer period of time,” said Norman “Chip” Harbaugh, M.D., F.A.A.P. of the Children’s Medical Group of Atlanta. “Early availability of FluMist gives providers the ability to reach more eligible children through back-to-school check-ups, sports physicals and annual well-child visits with a vaccine that has been shown to provide protection throughout the entire flu season.”
Record Number of FluMist Doses Available – and in More Locations
MedImmune will make FluMist more widely available than ever before, with plans to produce approximately 12 million doses for the 2008-2009 season. In addition to ongoing shipments to healthcare provider offices and clinics, FluMist will also be available this influenza season at select retail pharmacies and supermarkets. Please visit http://www.flumist.com/ for information about availability of FluMist in local areas.
FluMist will also be available in nearly 200 school-based vaccination programs and university health centers. Additionally, the U.S. Department of Defense (DoD) has awarded MedImmune a contract for FluMist for the fourth consecutive year to help vaccinate eligible active duty military personnel and their families.
FluMist is available in every state through the federally funded Vaccines for Children (VFC) program, which provides vaccines at no cost to eligible children. FluMist is also covered by approximately 94 percent of private health plans which offer immunization benefits.
FluMist is a live attenuated influenza virus vaccine indicated for active immunization of individuals two to 49 years of age against influenza disease caused by influenza virus subtypes A and type B contained in the vaccine.
FluMist is contraindicated in individuals with history of hypersensitivity to eggs, egg proteins, gentamicin, gelatin or arginine or with life-threatening reactions to previous influenza vaccinations, and in children and adolescents receiving concomitant aspirin or aspirin-containing therapy.
Do not administer FluMist to children less than two years of age due to an increased risk of hospitalization and wheezing that was observed in clinical trials. FluMist should not be administered to any individual with asthma and to children less than five years of age with recurrent wheezing unless the potential benefit outweighs the potential risk. Do not administer FluMist to individuals with severe asthma or active wheezing.
If Guillain-Barre syndrome has occurred with prior influenza vaccination or if an individual is immunocompromised, the decision to give FluMist should be based on careful consideration of the potential benefits and risks. FluMist should not be administered to individuals with underlying medical conditions predisposing them to wild-type influenza infection complications unless the potential benefit outweighs the potential risk. FluMist should be given to a pregnant woman only if clearly needed.
Most common adverse reactions (occurring in 10 percent or more of individuals receiving FluMist and at a rate at least five percent higher than in those receiving placebo) are runny nose or nasal congestion in recipients of all ages, fever more than 100 degrees F in children two to six years of age, and sore throat in adults.
FluMist may not protect all individuals receiving the vaccine. FluMist is for intranasal administration only.
Please see complete Prescribing Information for FluMist, call 1-877-FLUMIST (1-877-358-6478) or visit http://www.medimmune.com/pdf/products/flumist_pi.pdf for additional information.
MedImmune is wholly owned by AstraZeneca plc and is the worldwide biologics business for the AstraZeneca Group. The company has approximately 3,000 employees worldwide and is headquartered in Gaithersburg, Maryland. MedImmune strives to provide better medicines to patients, new medical options for physicians and rewarding careers to employees. Dedicated to advancing science and medicine to help people live better lives, the company is focused on infection, oncology, respiratory disease and inflammation, cardiovascular/gastrointestinal disease and neuroscience. For more information, visit MedImmune’s website at http://www.medimmune.com/ .
Photo: NewsCom: http://www.newscom.com/cgi-bin/prnh/20080804/NEM027AP Archive: http://photoarchive.ap.org/AP PhotoExpress Network: PRN10PRN Photo Desk, firstname.lastname@example.org
CONTACT: Media, Karen Lancaster, +1-301-398-5864, or Investors, PeterVozzo, +1-301-398-4358, both of MedImmune
Web site: http://www.medimmune.com/http://www.flumist.com/http://www.flumist.com/prescribing-information.aspx